Concepts (301)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adipose Tissue | 14 | 2020 | 511 | 3.720 |
Why?
|
| Monocytes | 14 | 2025 | 344 | 3.360 |
Why?
|
| Obesity | 20 | 2020 | 2396 | 2.510 |
Why?
|
| CD11c Antigen | 11 | 2021 | 40 | 2.330 |
Why?
|
| Atherosclerosis | 10 | 2025 | 1000 | 2.090 |
Why?
|
| Insulin Resistance | 13 | 2021 | 696 | 1.940 |
Why?
|
| Inflammation | 13 | 2020 | 1522 | 1.430 |
Why?
|
| T-Lymphocytes | 7 | 2019 | 1758 | 1.190 |
Why?
|
| Fatty Acids | 2 | 2020 | 357 | 1.070 |
Why?
|
| Foam Cells | 3 | 2025 | 24 | 0.970 |
Why?
|
| Diet, High-Fat | 7 | 2025 | 255 | 0.960 |
Why?
|
| Hypercholesterolemia | 5 | 2020 | 237 | 0.960 |
Why?
|
| Intra-Abdominal Fat | 3 | 2017 | 60 | 0.940 |
Why?
|
| Panniculitis | 3 | 2016 | 19 | 0.920 |
Why?
|
| STAT1 Transcription Factor | 2 | 2020 | 76 | 0.830 |
Why?
|
| Apolipoproteins E | 7 | 2017 | 201 | 0.700 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.680 |
Why?
|
| Diet, Western | 2 | 2019 | 18 | 0.670 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2018 | 210 | 0.660 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 449 | 0.660 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 32 | 0.630 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2001 | 65 | 0.630 |
Why?
|
| Macrophages | 3 | 2018 | 693 | 0.610 |
Why?
|
| CD18 Antigens | 5 | 2017 | 44 | 0.600 |
Why?
|
| Hypertriglyceridemia | 3 | 2017 | 114 | 0.600 |
Why?
|
| Weight Loss | 4 | 2011 | 515 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 21 | 2025 | 4764 | 0.580 |
Why?
|
| Lymphocyte Activation | 3 | 2021 | 686 | 0.570 |
Why?
|
| Myositis | 2 | 2017 | 105 | 0.570 |
Why?
|
| Immunity | 1 | 2018 | 183 | 0.550 |
Why?
|
| Mice, Knockout | 18 | 2025 | 3873 | 0.550 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 65 | 0.540 |
Why?
|
| Metabolic Diseases | 2 | 2018 | 139 | 0.530 |
Why?
|
| Muscle, Skeletal | 4 | 2017 | 1038 | 0.520 |
Why?
|
| Cytokines | 3 | 2020 | 1367 | 0.520 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 2017 | 110 | 0.520 |
Why?
|
| Animals | 33 | 2025 | 34953 | 0.520 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 81 | 0.510 |
Why?
|
| Proprotein Convertase 9 | 1 | 2017 | 82 | 0.510 |
Why?
|
| Dietary Supplements | 1 | 2020 | 439 | 0.510 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 382 | 0.500 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2013 | 57 | 0.490 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2017 | 111 | 0.490 |
Why?
|
| Mice | 27 | 2025 | 18566 | 0.480 |
Why?
|
| Cholesterol, VLDL | 1 | 2015 | 18 | 0.480 |
Why?
|
| Antigens, CD | 5 | 2001 | 437 | 0.470 |
Why?
|
| Blood Platelets | 5 | 2016 | 325 | 0.470 |
Why?
|
| Triglycerides | 4 | 2017 | 617 | 0.460 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 239 | 0.440 |
Why?
|
| Membrane Glycoproteins | 5 | 2001 | 421 | 0.440 |
Why?
|
| Liver | 6 | 2012 | 1806 | 0.440 |
Why?
|
| Immunity, Mucosal | 1 | 2014 | 94 | 0.440 |
Why?
|
| CD36 Antigens | 4 | 2019 | 42 | 0.430 |
Why?
|
| Aging | 2 | 2018 | 1253 | 0.430 |
Why?
|
| CD11a Antigen | 1 | 2013 | 12 | 0.420 |
Why?
|
| Flow Cytometry | 6 | 2020 | 806 | 0.420 |
Why?
|
| Interleukins | 1 | 2014 | 129 | 0.420 |
Why?
|
| Aorta | 3 | 2020 | 554 | 0.420 |
Why?
|
| Dietary Fats | 4 | 2014 | 279 | 0.410 |
Why?
|
| Aortic Diseases | 1 | 2015 | 197 | 0.400 |
Why?
|
| Lipoproteins, VLDL | 1 | 2012 | 53 | 0.380 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 4694 | 0.370 |
Why?
|
| CD11b Antigen | 3 | 2009 | 39 | 0.360 |
Why?
|
| CD11 Antigens | 2 | 2017 | 11 | 0.360 |
Why?
|
| Integrin alpha Chains | 2 | 2017 | 15 | 0.360 |
Why?
|
| Antibodies, Monoclonal | 5 | 2001 | 1038 | 0.350 |
Why?
|
| Phenotype | 2 | 2020 | 4541 | 0.350 |
Why?
|
| Dendritic Cells | 3 | 2021 | 448 | 0.340 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2010 | 29 | 0.340 |
Why?
|
| Anti-Obesity Agents | 1 | 2010 | 44 | 0.330 |
Why?
|
| Endothelium, Vascular | 3 | 2021 | 492 | 0.300 |
Why?
|
| Piperidines | 1 | 2010 | 236 | 0.290 |
Why?
|
| Leukocytes | 1 | 2009 | 209 | 0.290 |
Why?
|
| Pyrazoles | 1 | 2010 | 330 | 0.280 |
Why?
|
| Adiponectin | 2 | 2013 | 128 | 0.280 |
Why?
|
| Humans | 31 | 2025 | 132105 | 0.270 |
Why?
|
| Hyperlipidemias | 2 | 2025 | 188 | 0.270 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 2059 | 0.270 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 52 | 0.260 |
Why?
|
| HIV Infections | 1 | 2019 | 2050 | 0.260 |
Why?
|
| Cells, Cultured | 5 | 2021 | 3061 | 0.260 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 922 | 0.250 |
Why?
|
| Adipocytes | 4 | 2020 | 182 | 0.250 |
Why?
|
| Chemokine CCL2 | 3 | 2011 | 119 | 0.240 |
Why?
|
| Inflammation Mediators | 4 | 2017 | 241 | 0.240 |
Why?
|
| Weight Gain | 3 | 2013 | 379 | 0.230 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2020 | 68 | 0.230 |
Why?
|
| Body Weight | 1 | 2009 | 993 | 0.230 |
Why?
|
| Male | 20 | 2025 | 64918 | 0.230 |
Why?
|
| Apolipoprotein C-III | 1 | 2025 | 46 | 0.220 |
Why?
|
| Superantigens | 1 | 2004 | 20 | 0.220 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2025 | 79 | 0.220 |
Why?
|
| Adiposity | 2 | 2018 | 207 | 0.220 |
Why?
|
| Neoplasms | 1 | 2019 | 2953 | 0.220 |
Why?
|
| Platelet Activation | 3 | 1999 | 70 | 0.220 |
Why?
|
| Listeriosis | 1 | 2003 | 21 | 0.210 |
Why?
|
| Gene Knockdown Techniques | 1 | 2025 | 399 | 0.210 |
Why?
|
| Th1 Cells | 2 | 2021 | 159 | 0.190 |
Why?
|
| Interferon-gamma | 4 | 2021 | 539 | 0.180 |
Why?
|
| Spleen | 2 | 2018 | 272 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 503 | 0.180 |
Why?
|
| Lipoproteins, LDL | 2 | 2019 | 134 | 0.180 |
Why?
|
| Receptors, Fc | 1 | 2001 | 33 | 0.170 |
Why?
|
| Interleukin-5 | 1 | 2020 | 48 | 0.170 |
Why?
|
| Metabolic Syndrome | 3 | 2016 | 365 | 0.170 |
Why?
|
| Receptors, LDL | 2 | 2025 | 105 | 0.170 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2020 | 19 | 0.170 |
Why?
|
| Time Factors | 4 | 2015 | 6445 | 0.160 |
Why?
|
| Integrin alpha4beta1 | 2 | 2020 | 31 | 0.160 |
Why?
|
| Kupffer Cells | 1 | 2020 | 21 | 0.160 |
Why?
|
| Platelet Aggregation | 2 | 1999 | 107 | 0.160 |
Why?
|
| Receptors, Calcitriol | 1 | 2020 | 61 | 0.160 |
Why?
|
| Hepatitis | 1 | 2020 | 58 | 0.160 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Membrane Microdomains | 2 | 2016 | 61 | 0.150 |
Why?
|
| Models, Immunological | 1 | 2018 | 37 | 0.150 |
Why?
|
| Blotting, Western | 1 | 2020 | 1085 | 0.150 |
Why?
|
| CD47 Antigen | 1 | 2018 | 11 | 0.140 |
Why?
|
| Postprandial Period | 2 | 2016 | 91 | 0.140 |
Why?
|
| Adoptive Transfer | 3 | 2014 | 241 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2021 | 617 | 0.140 |
Why?
|
| Signal Transduction | 2 | 2021 | 4725 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1292 | 0.140 |
Why?
|
| Adaptive Immunity | 1 | 2018 | 94 | 0.140 |
Why?
|
| Protein Kinases | 1 | 2019 | 331 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2015 | 140 | 0.130 |
Why?
|
| Receptors, CCR2 | 1 | 2017 | 24 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 1723 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2017 | 106 | 0.130 |
Why?
|
| Lipid Droplets | 1 | 2017 | 50 | 0.130 |
Why?
|
| Cell Line | 3 | 2020 | 2730 | 0.130 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 74 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 234 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2009 | 2679 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2017 | 281 | 0.130 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 11 | 0.130 |
Why?
|
| Female | 13 | 2020 | 70680 | 0.130 |
Why?
|
| Cell Movement | 2 | 2017 | 891 | 0.120 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 43 | 0.120 |
Why?
|
| Glucose | 2 | 2020 | 878 | 0.120 |
Why?
|
| Drugs, Chinese Herbal | 1 | 1996 | 21 | 0.120 |
Why?
|
| Receptors, Ghrelin | 1 | 2016 | 30 | 0.120 |
Why?
|
| Macrophages, Peritoneal | 1 | 2016 | 39 | 0.120 |
Why?
|
| Calcium | 3 | 2001 | 1083 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2021 | 1121 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2021 | 1050 | 0.120 |
Why?
|
| Macrophage Activation | 2 | 2020 | 65 | 0.120 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 48 | 0.120 |
Why?
|
| Up-Regulation | 4 | 2017 | 880 | 0.120 |
Why?
|
| Glucose Intolerance | 2 | 2021 | 85 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 2922 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 422 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 153 | 0.110 |
Why?
|
| Cell Adhesion | 2 | 2015 | 327 | 0.110 |
Why?
|
| Osteonectin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Lymphopenia | 1 | 2014 | 39 | 0.100 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2014 | 46 | 0.100 |
Why?
|
| Mice, Obese | 1 | 2013 | 76 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 606 | 0.100 |
Why?
|
| Interleukin-18 | 1 | 2013 | 68 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 892 | 0.100 |
Why?
|
| Interleukin-12 | 1 | 2013 | 122 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2014 | 129 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2014 | 98 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2512 | 0.100 |
Why?
|
| Adult | 6 | 2020 | 31557 | 0.100 |
Why?
|
| Palmitic Acid | 1 | 2012 | 29 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 246 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2444 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 114 | 0.090 |
Why?
|
| Metalloendopeptidases | 1 | 2011 | 100 | 0.090 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 40 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3418 | 0.090 |
Why?
|
| Thrombosis | 1 | 2016 | 530 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 1993 | 207 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 666 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2013 | 242 | 0.090 |
Why?
|
| Insulin | 2 | 2013 | 1168 | 0.080 |
Why?
|
| Caloric Restriction | 1 | 2011 | 97 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1408 | 0.080 |
Why?
|
| Prognosis | 1 | 2020 | 5008 | 0.080 |
Why?
|
| E-Selectin | 1 | 2009 | 39 | 0.080 |
Why?
|
| Fatty Liver | 1 | 2011 | 211 | 0.080 |
Why?
|
| Chemokines | 1 | 2009 | 130 | 0.080 |
Why?
|
| Diet, Reducing | 1 | 2009 | 94 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 106 | 0.070 |
Why?
|
| Energy Intake | 1 | 2010 | 493 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 828 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1997 | 0.070 |
Why?
|
| Protein Conformation | 2 | 1999 | 825 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2012 | 799 | 0.070 |
Why?
|
| Chemotactic Factors | 1 | 2007 | 16 | 0.070 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 31 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2020 | 15 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2007 | 92 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2014 | 1975 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 1554 | 0.060 |
Why?
|
| Diet | 2 | 2010 | 1124 | 0.060 |
Why?
|
| Chemokines, CC | 1 | 2005 | 27 | 0.060 |
Why?
|
| Aged | 3 | 2020 | 21413 | 0.060 |
Why?
|
| 3T3-L1 Cells | 2 | 2015 | 58 | 0.060 |
Why?
|
| Ionomycin | 1 | 2004 | 18 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2004 | 63 | 0.060 |
Why?
|
| Enterotoxins | 1 | 2004 | 82 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2003 | 32 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2003 | 87 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2004 | 344 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 266 | 0.050 |
Why?
|
| Middle Aged | 3 | 2020 | 28936 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2003 | 249 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 868 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 351 | 0.050 |
Why?
|
| Neutrophils | 1 | 2003 | 360 | 0.040 |
Why?
|
| Receptors, Leptin | 1 | 2021 | 42 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2021 | 117 | 0.040 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2020 | 9 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2020 | 19 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2021 | 62 | 0.040 |
Why?
|
| Receptors, Interferon | 1 | 2020 | 22 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2003 | 413 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2020 | 62 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2001 | 120 | 0.040 |
Why?
|
| Biomarkers | 1 | 2009 | 3380 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 1999 | 29 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 648 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 288 | 0.040 |
Why?
|
| Biological Transport, Active | 2 | 1996 | 76 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 20532 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 516 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 1052 | 0.040 |
Why?
|
| Talin | 1 | 2018 | 11 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 796 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2453 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 473 | 0.040 |
Why?
|
| Vitamin D | 1 | 2020 | 180 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 1161 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1351 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 530 | 0.030 |
Why?
|
| Peritonitis | 1 | 2017 | 76 | 0.030 |
Why?
|
| Binding Sites | 1 | 1999 | 1256 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2020 | 549 | 0.030 |
Why?
|
| Cricetulus | 1 | 2016 | 93 | 0.030 |
Why?
|
| Homeostasis | 1 | 2020 | 723 | 0.030 |
Why?
|
| CHO Cells | 1 | 2016 | 158 | 0.030 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2020 | 304 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 621 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 46 | 0.030 |
Why?
|
| Paxillin | 1 | 2015 | 13 | 0.030 |
Why?
|
| Hormone Antagonists | 1 | 2016 | 49 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2015 | 14 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2015 | 35 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1995 | 30 | 0.030 |
Why?
|
| Lipolysis | 1 | 2016 | 75 | 0.030 |
Why?
|
| Microfluidics | 1 | 2015 | 28 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 430 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2020 | 784 | 0.030 |
Why?
|
| Cell Plasticity | 1 | 2016 | 35 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 96 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 333 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2016 | 194 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 618 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 285 | 0.030 |
Why?
|
| Proinsulin | 1 | 2013 | 13 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 306 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 59 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 83 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2013 | 1700 | 0.030 |
Why?
|
| Epitopes | 1 | 1995 | 436 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 63 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2009 | 13017 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1996 | 289 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 305 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 100 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 1993 | 72 | 0.020 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1993 | 38 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2014 | 181 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 164 | 0.020 |
Why?
|
| Fasting | 1 | 2013 | 301 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2013 | 206 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1735 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1993 | 121 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 436 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 234 | 0.020 |
Why?
|
| ADAMTS13 Protein | 1 | 2011 | 67 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1993 | 590 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 1606 | 0.020 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2010 | 37 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 349 | 0.020 |
Why?
|
| Gestational Age | 1 | 2013 | 1227 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2010 | 188 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1564 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 1349 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1879 | 0.020 |
Why?
|
| Chemokine CCL11 | 1 | 2005 | 12 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2005 | 124 | 0.020 |
Why?
|
| Species Specificity | 1 | 2005 | 544 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 3738 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3358 | 0.010 |
Why?
|
| Body Composition | 1 | 2005 | 549 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 549 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7551 | 0.010 |
Why?
|